Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya

Infectious Agents and Cancer
Naftali BusakhalaPatrick J Loehrer

Abstract

AIDS-related Kaposi sarcoma (AIDS-KS), a common malignancy in Kenya is associated with high morbidity and mortality. AIDS-KS is treated using bleomycin and vincristine (BV) plus or minus doxorubicin in most low resource settings, with response rates ranging from 24.8 to 87%. Survival in low resource settings has not been well documented. We report the three-year survival in a cohort of seventy patients referred to Moi Teaching and Referral Hospital (MTRH). Study participants are part of a randomized phase IIA trial on the use of gemcitabine compared to bleomycin plus vincristine for the treatment of Kaposi sarcoma after combination antiretroviral therapy (cART) in Western Kenya. All patients were followed for three years in MTRH. Survival was determined by three monthly physical examination and analysed using Kaplan-Meier method, while possible determinants of survival such as baseline characteristics, type of chemotherapy, initial CD4 counts, age at enrolment, gender and early response to chemotherapy were analysed using univariate and multivariate Cox regression. Participants were aged between 19 and 70 years with 56% being male. The median CD4 count was 224 cells/μl, median duration of HIV diagnosis was 12.0 months and media...Continue Reading

References

Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GillM E Ross
Sep 19, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E KrownJ Huang
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D W NorthfeltD H Henry
Jan 29, 2003·The Journal of Infectious Diseases·Ludo LavreysJoan K Kreiss
May 17, 2003·The Journal of Infectious Diseases·Sam M MbulaiteyeRobert J Biggar
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guglielmo NastiUNKNOWN AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian
Feb 2, 2013·Archives of Pathology & Laboratory Medicine·Oana Radu, Liron Pantanowitz
Jan 1, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark BowerMark Nelson
Jul 4, 2015·International Journal of Cancer. Journal International Du Cancer·Anne KorirMax Parkin
Dec 30, 2015·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Rodgers LupiaFeng-Jen Tsai
Jan 21, 2017·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Fred OkukuWarren Phipps
Aug 23, 2017·PloS One·Kathryn E RoyseElizabeth Y Chiao
Oct 13, 2017·South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde·M M SengayiJ Bohlius
Feb 2, 2018·Infectious Agents and Cancer·Vini FardhdianiMatthew E Coldiron

❮ Previous
Next ❯

Citations

Jul 18, 2021·Archives of Dermatological Research·Areti GkantaifiMaria Tolia

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Software Mentioned

AMPATH

Related Concepts

Related Feeds

Bacterial Vaginosis

Bacterial vaginosis can increase the risk of sexually transmitted infections and in rare cases lead to pelvic inflammatory diseases. Discover the latest research on Bacterial Vaginosis here.

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.